Member Info for Flippineck

When Launch Diagnostics was acquired in 2022 their 2021 financial year showed £14.17m non Covid revenue and total revenue inc Covid products of £32.75m. Since 2019 the gross margin in total sales had been consistently in the range of 44 - 50% across all products.

I am hopeful that both Launch and Coris will be producing decent profits for Avacta, thereby reducing cash burn.

Our stock market expert and Lecturer in Chief doesn’t seem to have even considered the licensing option, with a nice up front cash payment.

Limited imagination!

McMuff, you don’t post much but your posts do show a strong understanding of the science and the company. You show quiet confidence in a successful outcome.

Avacta seems to display the same confidence- witness the way the trial has been adapted, the switch towards the USA and the very high profile hiring of senior personnel. They seem relaxed.

This is in stark contrast to the naysayers on here who post more and more about less and less. A sense of panic seems to have set in with them.

The share price feels almost like it’s being controlled. The company is being very quiet on the news front. I, like a number of others, feel something is brewing.

News of some sort really can’t be too far away. We can but wait.

GLA.

BV. I must admit I had not considered the cost of the US trials and whether patients/ health insurers would have to pay.

I had assumed Avacta would cover these costs- do you think that is likely? I imagine they wouldn’t want to put obstacles in the way of patients they felt would be suitable.

This, to me, is a very interesting thread. I particularly liked Rambo’s post last night.

I suppose if 2 parties were in late stage discussions they would want to keep things as quiet as possible. Nobody would want to rock the boat and an acquirer or licensee wouldn’t want too much news coming out as things progressed.

Obviously pure speculation. GLA.

Timster, I understand the point you make. However this isn’t a new drug, it is a new delivery system for a well known and established drug.

In addition a clinician can point out the outstanding results so far. The difference now is 2 week dosing as opposed to three weekly.

Admittedly I am a layman but I would have thought it would not be too difficult to get volunteers. The issue may be that we are being super selective in who we accept?

Either way we have now waited a long time for an update and I’m hoping one is just round the corner.

GLA.

Earlier this week Livedata suggested the company “ need to up their game with comms”.

I wonder if there is any chance he could do the same with his repetitive postings?

Viking, you seem to know a lot about how things work - or do you?

Only a few days ago you posted on the GGP board “Just looking to buy in do they actually mine and sell gold or is it just exploration”

Your deep research is always appreciated!

Exactly Icecool- and I think it will send out a very powerful message when we do.

It would send out a very interesting message if the loan repayment was made in cash!

President,development and chief medical officer Novartis

I agree Johnson and Johnson will know about us, as will all the big Pharma, I believe. They must have the equivalent of football scouts to keep abreast of developments and potential breakthrough technologies.

What does puzzle me (and I know it has been said before) is how much under the radar we are with the wider investment community. If you try googling doxorubicin pro- drugs, or cancer breakthrough technology you will be hard-pressed to see anything about Avacta.

It makes me believe that the share price will be catapulted into orbit when significant good news finally breaks, coupled with the appropriate press coverage. The “good news” could come in many different forms.

We just have to wait.

Is coming to an end towards the end of this decade for many drugs.

Isn’t it true that by re-packaging those drugs through a new delivery platform can renew and extend the patent protection?

If so , that will have massive appeal for big Pharma as it retains their exclusivity.

Talking of trolls, one of our (very) regular ones posted only this morning . The gist of his post , referring to “the presentation”, was “ I’ll have a listen at some point”!

He doesn’t seem to read RNS’s or listen to presentations, yet forever tells us of his concerns.

Perhaps he could listen more and post less? Probably that’s too much to hope of somebody who is not invested.

Top tips include a biotech investment trust, a gold miner and a copper ETF.

RTW Biotech Opportunities (tipped) doesn’t appear to have a shareholding in Avacta, however they feel there is a “unique opportunity to buy into a depressed market while innovation is booming”. They say the Russell 2000 Biotech index is “ three months short of the longest ever bear market and down 75% from its peak”. The RTW share price is back to its October 2019 issue price.

The tide can turn, perhaps 2024 could be that year? In my view there is certainly the good chance a number of events could come together which could create a whiplash increase in our share price.

Time will tell. Good luck all.

Thank you Almostrich for such a detailed post. Invaluable for a non scientist such as me.

If all goes well will you be changing your name to Filthyrich!

Merry Christmas to you also.

Sad to see the usual culprits try to put a negative spin on good news.

So far as Dr Tap is concerned- he is a professional and will not be shouting hurrahs part way through a trial. He needs proof positive my dear Hastings as Poirot would say. He simply can’t afford to get too excited too soon.

How quickly the mood can change! So many things seem to be coming together in such a short space of time.

Some commented that Alastair sounded a bit weary on the Paul Hill interview. No wonder - bet he’s been in meeting after meeting at an ever accelerating pace. Burning the midnight oil for sure. He and the team can have a well earned break over Christmas.

Slowly, slowly then suddenly.

In March our friend Viking told us this was going to 50p. Can’t see it myself but time will tell how accurate his predictions are.

Totally agree Donkeyeeyore.

Think of large civil engineering projects, think of Grand Designs or indeed smallish building projects. More often than not unexpected issues arise, budgets get blown out of the water and more funding is needed to get the job done.

Why would anybody think a small company, developing ground-breaking technology, be any different. Avacta has to navigate all these issues.

Folks need to be realistic and believe in what the company is doing. If they don’t then I’m unsure why they remain invested.